electroCore, Inc. (ECOR) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 7.24%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value -1159.42×; Formula and calculation Operating income ÷ reported interest expense..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | 7.24% | Share-based compensation / revenue. Period ending 2026-06-30. $2.68M ÷ $36.97M × 100 ≈ 7.24% |
| Interest coverage · 12 months | -1159.42× | Operating income ÷ reported interest expense. $-13.91M ÷ $12.00K ≈ -1159.42× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | (m) | Research and Development Expense |
| Revenue | 36.97M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 2.68M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -13.91M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | 12.00K USD | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: Reported. Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $36.97M | $2.68M | $-13.91M | $12.00K | (m) | 7.24% | -1159.42× | Reported |
| 2026-03-31 | (m) | $34.90M | $2.43M | $-14.65M | $13.90K | (m) | 6.95% | -1053.74× | Reported |
| 2025-12-31 | (m) | $32.03M | $1.93M | $-13.15M | $14.90K | (m) | 6.03% | -882.75× | Reported |
| 2025-09-30 | $2.62M | $29.84M | $1.97M | $-13.28M | (m) | 8.78% | 6.62% | (m) | (m) |
| 2025-06-30 | $2.48M | $27.70M | $1.96M | $-13.05M | (m) | 8.95% | 7.07% | (m) | (m) |
| 2025-03-31 | $2.60M | $26.46M | $1.93M | $-12.13M | (m) | 9.84% | 7.28% | (m) | (m) |
| 2024-12-31 | $2.36M | $25.18M | $1.87M | $-12.16M | (m) | 9.37% | 7.43% | (m) | (m) |
| 2024-09-30 | $2.66M | (m) | $1.76M | $-13.05M | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $3.39M | $21.28M | $1.90M | $-14.52M | (m) | 15.93% | 8.92% | (m) | (m) |
| 2024-03-31 | $3.91M | $18.69M | $1.61M | $-16.92M | (m) | 20.92% | 8.61% | (m) | (m) |
| 2023-12-31 | $5.32M | (m) | $1.70M | $-19.27M | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | $5.84M | $13.40M | $1.89M | $-21.23M | (m) | 43.59% | 14.07% | (m) | (m) |
| 2023-06-30 | $6.21M | $10.87M | $1.91M | $-22.66M | (m) | 57.14% | 17.56% | (m) | (m) |
| 2023-03-31 | $6.39M | $9.47M | $2.48M | $-23.49M | (m) | 67.51% | 26.15% | (m) | (m) |
| 2022-12-31 | $5.52M | $8.59M | $2.68M | $-22.87M | $4.00K | 64.25% | 31.22% | -5718.50× | Reported |
| 2022-09-30 | $4.63M | $7.52M | $2.86M | $-22.43M | (m) | 61.59% | 37.96% | (m) | (m) |
| 2022-06-30 | $3.49M | $7.03M | $3.05M | $-20.86M | (m) | 49.57% | 43.38% | (m) | (m) |
| 2022-03-31 | $2.97M | $6.15M | $3.14M | $-20.24M | (m) | 48.34% | 51.04% | (m) | (m) |
| 2021-12-31 | $2.54M | $5.45M | $3.30M | $-20.04M | (m) | 46.52% | 60.58% | (m) | (m) |
| 2021-09-30 | $2.81M | $4.89M | $3.32M | $-20.89M | (m) | 57.54% | 67.84% | (m) | (m) |
| 2021-06-30 | $2.97M | $4.48M | $3.30M | $-21.40M | (m) | 66.29% | 73.60% | (m) | (m) |
| 2021-03-31 | $3.18M | $3.97M | $3.46M | $-22.12M | (m) | 80.11% | 87.34% | (m) | (m) |
| 2020-12-31 | $4.20M | $3.50M | $3.27M | $-24.75M | (m) | 120.18% | 93.43% | (m) | (m) |
| 2020-09-30 | $4.81M | $3.24M | $3.70M | $-27.03M | (m) | 148.20% | 113.98% | (m) | (m) |
| 2020-06-30 | $6.49M | $2.84M | $4.17M | $-33.43M | (m) | 227.99% | 146.68% | (m) | (m) |
| 2020-03-31 | $7.97M | $2.71M | $3.90M | $-39.89M | (m) | 293.45% | 143.55% | (m) | (m) |
| 2019-12-31 | $9.90M | $2.39M | $3.90M | $-46.09M | (m) | 414.27% | 162.98% | (m) | (m) |
| 2019-09-30 | $11.74M | $2.08M | $3.83M | $-53.16M | (m) | 563.59% | 183.96% | (m) | (m) |
| 2019-06-30 | $11.76M | $1.55M | $3.44M | $-55.82M | (m) | 758.47% | 221.73% | (m) | (m) |
| 2019-03-31 | $13.62M | $1.32M | $8.08M | $-59.67M | (m) | 1030.72% | 611.21% | (m) | (m) |
| 2018-12-31 | $12.47M | $992.95K | $7.60M | $-54.55M | (m) | 1255.46% | 765.34% | (m) | (m) |
| 2018-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | $775.46K | (m) | $-30.00M | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | $7.83M | $811.46K | $462.33K | $-25.64M | $6.30M | 965.04% | 56.98% | -4.07× | Reported |
| 2017-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neuraxis, INC (NRXS) | United States | $0.097B | |
| Nexalin Technology, Inc. (NXL) | United States | $0.094B | |
| Vivani Medical, Inc. (VANI) | United States | $0.111B | |
| Streamex Corp. (STEX) | United States | $0.089B | -0.19 |
| Stereotaxis, Inc. (STXS) | United States | $0.130B | -7.53 |
| Outset Medical, Inc. (OM) | United States | $0.059B | -1.09 |
| PRECISION OPTICS CORPORATION, INC. (POCI) | United States | $0.052B | |
| QT IMAGING HOLDINGS, INC. (QTI) | United States | $0.037B | |
| EDAP TMS SA (FOCL) | $0.171B | ||
| IRIDEX CORP (IRIX) | United States | $0.011B |